test
Monday, June 24, 2024

GSK shares tumble by most in two years after Zantac ruling

Must read




GSK shares dropped by the most in nearly two years after a ruling by the Delaware State Court that will allow jury trials in cases brought by cancer sufferers who say the heartburn drug Zantac caused their condition.



Source link

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article